risperidone has been researched along with Disease Models, Animal in 132 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Risperidone is the first antipsychotic to be approved by Food and Drug Administration (FDA) for treating autism spectrum disorder (ASD)." | 8.31 | The comparative effectiveness of metformin and risperidone in a rat model of valproic acid-induced autism, Potential role for enhanced autophagy. ( Ashour, RH; Atia, AA; Rahman, KM; Ramadan, NM; Zaki, MM, 2023) |
| "Risperidone, 5-HT2A receptor antagonists, and D1 receptor antagonistic drugs prevented and reversed cocaine-induced hyperthermia." | 7.96 | Risperidone and 5-HT2A Receptor Antagonists Attenuate and Reverse Cocaine-Induced Hyperthermia in Rats. ( Makiguchi, A; Okada, T; Shioda, K; Suda, S, 2020) |
| "Antipsychotic drugs plus aspirin (acetylsalicylic acid), which targets prostaglandin-endoperoxide synthase 1 (PTGS1: COX1), improved therapeutic outcomes when treating schizophrenia." | 7.88 | Studies on Prostaglandin-Endoperoxide Synthase 1: Lower Levels in Schizophrenia and After Treatment with Antipsychotic Drugs in Conjunction with Aspirin. ( Dean, B; Gibbons, A; Gogos, A; Scarr, E; Thomas, E; Udawela, M, 2018) |
| "Quinpirole (QNP) sensitization is one of the commonly used animal models of obsessive-compulsive disorder (OCD)." | 7.85 | Detrimental effect of clomipramine on hippocampus-dependent learning in an animal model of obsessive-compulsive disorder induced by sensitization with d2/d3 agonist quinpirole. ( Hatalova, H; Pistikova, A; Radostova, D; Stuchlik, A; Vales, K, 2017) |
| " The aim of this work was designed to investigate the diagnostic possibility of [(123)I]epidepride imaging platform for risperidone-treatment chronic MK-801-induced rat schizophrenia model." | 7.80 | Dopamine D(2)/D(3) receptor binding of [(123)I]epidepride in risperidone-treatment chronic MK-801-induced rat schizophrenia model using nanoSPECT/CT neuroimaging. ( Chang, KW; Chen, MW; Cheng, KH; Huang, YR; Kuo, WI; Pai, CW, 2014) |
| "In the present work we analyzed the effect of the chronic administration of risperidone (2mg/kg over 65 days) on behavioural, morphological and molecular aspects in an experimental model of schizophrenia obtained by bilateral injection of ibotenic acid into the ventral hippocampus of new-born rats." | 7.79 | Chronic administration of risperidone in a rat model of schizophrenia: a behavioural, morphological and molecular study. ( Arji, M; Carro, J; Castellano, O; de Anchieta de Castro E Horta, J; Gómez-Nieto, R; Herrero-Turrión, MJ; López, DE; Molina, V; Riolobos, AS; Sancho, C, 2013) |
| "Several clinical reports have suggested that the mirtazapine-induced augmentation of risperidone activity may effectively improve the positive, negative and some cognitive symptoms of schizophrenia." | 7.78 | Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. ( Rogóż, Z, 2012) |
| "Weight gain and metabolic disturbances, such as dyslipidemia and hyperglycaemia, are common side effects of most antipsychotic drugs, including risperidone." | 7.77 | Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver. ( Bordet, R; Bouchaert, E; Cussac, D; Duriez, P; Helleboid, A; Hum, D; Lauressergues, E; Luc, G; Majd, Z; Martin, F; Staels, B, 2011) |
| "Risperidone has been shown to be clinically effective for the treatment of aggressive behavior in children, yet until recently no information was available regarding whether risperidone exhibits aggression-specific suppression in preclinical studies employing validated developmentally immature animal models of escalated aggression." | 7.74 | Repeated risperidone administration during puberty prevents the generation of the aggressive phenotype in a developmentally immature animal model of escalated aggression. ( Connor, DF; Melloni, RH; Morrison, RL; Ricci, LA; Schwartzer, JJ, 2008) |
| "These studies provide evidence that risperidone exerts specific aggression-suppressing effects in a developmentally immature animal model of escalated aggression." | 7.74 | Risperidone exerts potent anti-aggressive effects in a developmentally immature animal model of escalated aggression. ( Connor, DF; Melloni, RH; Morrison, R; Ricci, LA, 2007) |
| " In the present study, we examined the effect of perospirone on marble-burying behavior, which has been considered an animal model of obsessive-compulsive disorder (OCD), compared with the effects of other antipsychotics such as haloperidol and risperidone." | 7.73 | Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder. ( Egashira, N; Fujiwara, M; Harada, S; Iwasaki, K; Matsushita, M; Mishima, K; Nishimura, R; Okuno, R, 2005) |
| "Risperidone is known to increase prolactin secretion in treating mental illness patients." | 5.46 | The central mechanism of risperidone-induced hyperprolactinemia. ( Huang, XF; Li, LY; Lin, S; Shi, YC; Song, ZY; Sun, WW; Yang, HQ, 2017) |
| "Cariprazine is a dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors, recently approved by the FDA for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder." | 5.43 | Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. ( Adham, N; Ferguson, P; Grayson, B; Gyertyán, I; Kiss, B; Neill, JC, 2016) |
| "Schizophrenia is a chronic and highly complex psychiatric disorder characterised by cognitive dysfunctions, negative and positive symptoms." | 5.38 | Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia. ( Adzu, B; Chindo, BA; Gamaniel, KS; Yahaya, TA, 2012) |
| "Schizophrenia is a disorder of a neurodevelopmental origin manifested symptomatically after puberty." | 5.37 | Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. ( Arad, M; Piontkewitz, Y; Weiner, I, 2011) |
| "Pretreatment with risperidone (0." | 5.32 | Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. ( Kato, S; Nisijima, K; Shioda, K; Takano, K; Yoshino, T, 2004) |
| "The therapeutic success of clozapine and risperidone has focused attention on the interaction between serotonin and dopamine systems as an avenue for superior therapeutics in schizophrenia." | 4.79 | Serotonin-dopamine interaction and its relevance to schizophrenia. ( Kapur, S; Remington, G, 1996) |
| "Risperidone is the first antipsychotic to be approved by Food and Drug Administration (FDA) for treating autism spectrum disorder (ASD)." | 4.31 | The comparative effectiveness of metformin and risperidone in a rat model of valproic acid-induced autism, Potential role for enhanced autophagy. ( Ashour, RH; Atia, AA; Rahman, KM; Ramadan, NM; Zaki, MM, 2023) |
| "Risperidone, 5-HT2A receptor antagonists, and D1 receptor antagonistic drugs prevented and reversed cocaine-induced hyperthermia." | 3.96 | Risperidone and 5-HT2A Receptor Antagonists Attenuate and Reverse Cocaine-Induced Hyperthermia in Rats. ( Makiguchi, A; Okada, T; Shioda, K; Suda, S, 2020) |
| "Antipsychotic drugs plus aspirin (acetylsalicylic acid), which targets prostaglandin-endoperoxide synthase 1 (PTGS1: COX1), improved therapeutic outcomes when treating schizophrenia." | 3.88 | Studies on Prostaglandin-Endoperoxide Synthase 1: Lower Levels in Schizophrenia and After Treatment with Antipsychotic Drugs in Conjunction with Aspirin. ( Dean, B; Gibbons, A; Gogos, A; Scarr, E; Thomas, E; Udawela, M, 2018) |
| "Rodents exposed prenatally to valproic acid (VPA) exhibit autism spectrum disorder (ASD)-like behavioral abnormalities." | 3.85 | Risperidone and aripiprazole alleviate prenatal valproic acid-induced abnormalities in behaviors and dendritic spine density in mice. ( Ago, Y; Hara, Y; Hasebe, S; Hashimoto, H; Kawase, H; Matsuda, T; Nakazawa, T; Takuma, K; Tanabe, W; Taruta, A; Tsukada, S, 2017) |
| "Quinpirole (QNP) sensitization is one of the commonly used animal models of obsessive-compulsive disorder (OCD)." | 3.85 | Detrimental effect of clomipramine on hippocampus-dependent learning in an animal model of obsessive-compulsive disorder induced by sensitization with d2/d3 agonist quinpirole. ( Hatalova, H; Pistikova, A; Radostova, D; Stuchlik, A; Vales, K, 2017) |
| "Immune dysregulation observed in schizophrenia alters tryptophan metabolism." | 3.85 | Reversal of schizophrenia-like symptoms and immune alterations in mice by immunomodulatory drugs. ( Cordeiro, RC; da Silva Araújo, T; de Freitas Lima, R; de Jesus Souza Machado, M; Freitas de Lucena, D; Isabelle de Góis Queiroz, A; Macêdo, D; Maes, M; Maia Chaves Filho, AJ; Monte, AS, 2017) |
| " Moreover we also investigated their utility as adjunct treatment in depression in combination with the SSRI citalopram." | 3.83 | Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study. ( Björkholm, C; Feltmann, K; Jardemark, K; Konradsson-Geuken, Å; Malmerfelt, A; Marcus, MM; Möller, A; Påhlsson, N; Schilström, B; Svensson, TH, 2016) |
| " Given the scarcity of adequate data on its prenatal toxicity, a comparative teratogenicity study of valnoctamide and two of the most commonly used drugs to treat bipolar disorder, risperidone and olanzapine, was carried out in a mouse model system." | 3.81 | Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice. ( Bialer, M; Finnell, RH; Lin, LY; Ogle, K; Wlodarczyk, BJ, 2015) |
| "Overall, our data suggest that maternal inflammation may contribute to an increased risk for schizophrenia through mechanisms involving metabolic function and myelin formation and that risperidone in adolescence may prevent or reverse such changes." | 3.81 | Maternal immune activation induces changes in myelin and metabolic proteins, some of which can be prevented with risperidone in adolescence. ( Cagney, G; Cannon, M; Cotter, DR; Dicker, P; English, J; Farrelly, L; Föcking, M; Piontkewitz, Y; Wynne, K, 2015) |
| " After 4-week administration, clozapine (10mg/kg/d) and risperidone (1mg/kg/d) both caused glucose intolerance and insulin resistance in VD deficient rats, but not in rats with sufficient VD status." | 3.81 | Vitamin D deficiency exacerbates atypical antipsychotic-induced metabolic side effects in rats: involvement of the INSIG/SREBP pathway. ( Cai, H; Dang, R; Guo, R; He, X; Jiang, P; Li, H; Liu, Y; Wu, Y; Xu, P; Zhang, L; Zhu, W, 2015) |
| " The aim of this work was designed to investigate the diagnostic possibility of [(123)I]epidepride imaging platform for risperidone-treatment chronic MK-801-induced rat schizophrenia model." | 3.80 | Dopamine D(2)/D(3) receptor binding of [(123)I]epidepride in risperidone-treatment chronic MK-801-induced rat schizophrenia model using nanoSPECT/CT neuroimaging. ( Chang, KW; Chen, MW; Cheng, KH; Huang, YR; Kuo, WI; Pai, CW, 2014) |
| " Given the potential of these drugs to modulate the immune system both peripherally and within the central nervous system, we investigated the ability of the atypical anti-psychotic agent, risperidone, to modify disease in the animal model of multiple sclerosis (MS)4, experimental autoimune encephalomyelitis (EAE)." | 3.80 | Treatment with the antipsychotic agent, risperidone, reduces disease severity in experimental autoimmune encephalomyelitis. ( Connor, B; Fong, D; Green, L; Kharkrang, M; La Flamme, AC; O'Sullivan, D; Stone, S; Zareie, P, 2014) |
| "In the present work we analyzed the effect of the chronic administration of risperidone (2mg/kg over 65 days) on behavioural, morphological and molecular aspects in an experimental model of schizophrenia obtained by bilateral injection of ibotenic acid into the ventral hippocampus of new-born rats." | 3.79 | Chronic administration of risperidone in a rat model of schizophrenia: a behavioural, morphological and molecular study. ( Arji, M; Carro, J; Castellano, O; de Anchieta de Castro E Horta, J; Gómez-Nieto, R; Herrero-Turrión, MJ; López, DE; Molina, V; Riolobos, AS; Sancho, C, 2013) |
| "Several clinical reports have suggested that the mirtazapine-induced augmentation of risperidone activity may effectively improve the positive, negative and some cognitive symptoms of schizophrenia." | 3.78 | Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. ( Rogóż, Z, 2012) |
| "Several clinical reports have postulated a beneficial effect of the addition of a low dose of risperidone to the ongoing treatment with antidepressants in treatment-resistant depression." | 3.78 | Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test. ( Gądek-Michalska, A; Kabziński, M; Rachwalska, P; Rogóż, Z; Sadaj, W, 2012) |
| "Perinatal phencyclidine (PCP) administration to rats represents one of the actual animal models of schizophrenia." | 3.78 | Risperidone reverses phencyclidine induced decrease in glutathione levels and alterations of antioxidant defense in rat brain. ( Doknić, M; Jevtić, G; Petronijević, ND; Popović, V; Radonjić, NV; Stojković, T; Velimirović, M, 2012) |
| "Weight gain and metabolic disturbances, such as dyslipidemia and hyperglycaemia, are common side effects of most antipsychotic drugs, including risperidone." | 3.77 | Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver. ( Bordet, R; Bouchaert, E; Cussac, D; Duriez, P; Helleboid, A; Hum, D; Lauressergues, E; Luc, G; Majd, Z; Martin, F; Staels, B, 2011) |
| "Epidermal growth factor (EGF) is one of the ErbB receptor ligands implicated in schizophrenia neuropathology as well as in dopaminergic development." | 3.77 | Pallidal hyperdopaminergic innervation underlying D2 receptor-dependent behavioral deficits in the schizophrenia animal model established by EGF. ( Aizawa, M; Iwakura, Y; Mizuno, M; Namba, H; Nawa, H; Shcherbakova, K; Sotoyama, H; Wang, R; Zheng, Y, 2011) |
| "Ketamine-induced alterations in EEG power spectra are consistent with abnormalities in the theta and gamma frequency ranges reported in patients with schizophrenia." | 3.75 | N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. ( Contreras, D; Ehrlichman, RS; Finkel, LH; Gandal, MJ; Lazarewicz, MT; Maxwell, CR; Siegel, SJ; Turetsky, BI, 2009) |
| "Clinical studies have reported the beneficial outcome of addition of lower doses of risperidone to antidepressant therapy specifically with selective serotonin reuptake inhibitors (SSRIs) in the treatment of major depression." | 3.74 | Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors. ( Dhir, A; Kulkarni, SK, 2008) |
| "Risperidone has been shown to be clinically effective for the treatment of aggressive behavior in children, yet until recently no information was available regarding whether risperidone exhibits aggression-specific suppression in preclinical studies employing validated developmentally immature animal models of escalated aggression." | 3.74 | Repeated risperidone administration during puberty prevents the generation of the aggressive phenotype in a developmentally immature animal model of escalated aggression. ( Connor, DF; Melloni, RH; Morrison, RL; Ricci, LA; Schwartzer, JJ, 2008) |
| "These studies provide evidence that risperidone exerts specific aggression-suppressing effects in a developmentally immature animal model of escalated aggression." | 3.74 | Risperidone exerts potent anti-aggressive effects in a developmentally immature animal model of escalated aggression. ( Connor, DF; Melloni, RH; Morrison, R; Ricci, LA, 2007) |
| "Disruptions in 5-CSRTT performance induced by repeated PCP administration are prevented by chronic clozapine treatment and may constitute a useful animal model of some cognitive symptoms of schizophrenia." | 3.74 | Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. ( Amitai, N; Markou, A; Semenova, S, 2007) |
| " In the present study, we examined the effect of perospirone on marble-burying behavior, which has been considered an animal model of obsessive-compulsive disorder (OCD), compared with the effects of other antipsychotics such as haloperidol and risperidone." | 3.73 | Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder. ( Egashira, N; Fujiwara, M; Harada, S; Iwasaki, K; Matsushita, M; Mishima, K; Nishimura, R; Okuno, R, 2005) |
| " To develop an animal model for the negative symptoms of schizophrenia, in particular, the depressive symptoms, the effect of phencyclidine (PCP) on immobility in the forced swimming test was investigated in mice, since PCP produces negative symptoms-like behavioral changes in humans." | 3.69 | [Behavioral assessment of neuroleptics (3)--Schizophrenia negative symptoms-like model induced by PCP]. ( Nabeshima, T; Noda, Y, 1996) |
| "All of the medications developed for treatment of psychosis rely on tertiary prevention, and there is no a priori reason to assume that these treatments would be the safest and most effective primary preventive treatment of first-episode psychosis." | 2.44 | Serotonin and dopamine interactions in psychosis prevention. ( McNamara, RK; Richtand, NM, 2008) |
| "Chronic risperidone did not reverse mania-like behavior in DAT knockdown mice." | 1.62 | Chronic antipsychotic treatment exerts limited effects on the mania-like behavior of dopamine transporter knockdown mice. ( Arnt, J; Bundgaard, C; Cope, ZA; Geyer, MA; Kenton, JA; Martin, MV; Minassian, A; Perry, W; van Enkhuizen, J; Young, JW, 2021) |
| "Cuprizone and drugs were administered to C57BL6/J mice for five weeks and locomotor activity, motor performance and cold sensitivity were assessed." | 1.62 | Effects of Venlafaxine, Risperidone and Febuxostat on Cuprizone-Induced Demyelination, Behavioral Deficits and Oxidative Stress. ( Andrei, C; Chirita, C; Ciotu, CI; Fischer, MJM; Mihai, DP; Negres, S; Nitulescu, GM; Olaru, OT; Seremet, OC; Ungurianu, A; Zanfirescu, A; Zbarcea, CE, 2021) |
| "Schizophrenia is a severe neuropsychiatric disease associated with substantially higher mortality." | 1.62 | Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue. ( Bienertova-Vasku, J; Horska, K; Hruska, P; Kucera, J; Kuruczova, D; Micale, V; Ruda-Kucerova, J, 2021) |
| "Risperidone and piracetam were found to be effective alone, while their high dose combination, produced potentiating effect in reversing the extinction deficit, behavioral alterations, altered cortical and hippocampal BDNF, IL-6, TNF-α, caspase-3, oxidative stress markers, and neurotransmitter levels." | 1.51 | Co-treatment of piracetam with risperidone rescued extinction deficits in experimental paradigms of post-traumatic stress disorder by restoring the physiological alterations in cortex and hippocampus. ( Akhtar, A; Bansal, Y; Kuhad, A; Sah, SP; Singh, R; Uniyal, A, 2019) |
| "Risperidone is known to increase prolactin secretion in treating mental illness patients." | 1.46 | The central mechanism of risperidone-induced hyperprolactinemia. ( Huang, XF; Li, LY; Lin, S; Shi, YC; Song, ZY; Sun, WW; Yang, HQ, 2017) |
| " First, we compared the PCP dose-response in the range of 1." | 1.43 | Comparison of phencyclidine-induced spatial learning and memory deficits and reversal by sertindole and risperidone between Lister Hooded and Wistar rats. ( Forsberg, MM; Ihalainen, J; Savolainen, K; Tanila, H, 2016) |
| "Cariprazine is a dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors, recently approved by the FDA for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder." | 1.43 | Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. ( Adham, N; Ferguson, P; Grayson, B; Gyertyán, I; Kiss, B; Neill, JC, 2016) |
| "Schizophrenia is associated with behavioral and brain structural abnormalities, of which the hippocampus appears to be one of the most consistent region affected." | 1.43 | Maturation- and sex-sensitive depression of hippocampal excitatory transmission in a rat schizophrenia model. ( Attali, B; Patrich, E; Peretz, A; Piontkewitz, Y; Weiner, I, 2016) |
| "Risperidone also has multiple receptor targets in which only a subset may be procognitive and others induce cognitive impairment." | 1.40 | Risperidone and the 5-HT2A receptor antagonist M100907 improve probabilistic reversal learning in BTBR T + tf/J mice. ( Amodeo, DA; Jones, JH; Ragozzino, ME; Sweeney, JA, 2014) |
| "The management for post-traumatic stress disorder (PTSD) involves chronic administration of drugs." | 1.39 | Risperidone ameliorates post-traumatic stress disorder-like symptoms in modified stress re-stress model. ( Garabadu, D; Joy, KP; Krishnamurthy, S, 2013) |
| "Schizophrenia is a chronic and highly complex psychiatric disorder characterised by cognitive dysfunctions, negative and positive symptoms." | 1.38 | Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia. ( Adzu, B; Chindo, BA; Gamaniel, KS; Yahaya, TA, 2012) |
| " In contrast, chronic administration of ketamine not only produced significant 'hyperactivity' response but also enhanced the immobility period in animals during the forced swim test and reduced the latency period in the passive avoidance test." | 1.37 | Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis. ( Chatterjee, M; Ganguly, S; Palit, G; Srivastava, M, 2011) |
| "Risperidone has been used in some stress disorders and may be potentially protective against stress-induced gastric lesions." | 1.37 | Gastroprotective potential of risperidone, an atypical antipsychotic, against stress and pyloric ligation induced gastric lesions. ( Krishnamurthy, S; Saxena, B; Singh, S, 2011) |
| "Schizophrenia is a disorder of a neurodevelopmental origin manifested symptomatically after puberty." | 1.37 | Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. ( Arad, M; Piontkewitz, Y; Weiner, I, 2011) |
| " Pharmacokinetic study showed that PDs were quickly metabolized to paliperidone to take effect in the treatment of schizophrenia in rats after i." | 1.36 | Studies on the acute toxicity, pharmacokinetics and pharmacodynamics of paliperidone derivatives--comparison to paliperidone and risperidone in mice and rats. ( Li, Y; Meng, Q; Su, Z; Sui, C; Sun, F; Teng, L; Yuan, L; Zhang, C, 2010) |
| "Asenapine was highly potent (active at 0." | 1.35 | Asenapine effects in animal models of psychosis and cognitive function. ( Azar, MR; Geyer, MA; Gold, L; Marston, HM; Martin, FD; Meltzer, LT; Moore, CL; Serpa, KA; Shahid, M; Wong, EH; Young, JW, 2009) |
| "Antipsychotic treatment during pregnancy is indicated when risk of drug exposure to the fetus is outweighed by the untreated psychosis in the mother." | 1.35 | Distinct neurobehavioral consequences of prenatal exposure to sulpiride (SUL) and risperidone (RIS) in rats. ( Hao, Y; Liu, H; Liu, Z; Lu, XH; Ouyang, X; Xu, L; Zuo, J, 2008) |
| "Treatment with risperidone for 8 weeks, but not 2 or 4 weeks, significantly improved working memory performance." | 1.34 | Propranolol blocks chronic risperidone treatment-induced enhancement of spatial working memory performance of rats in a delayed matching-to-place water maze task. ( Dawe, GS; Lim, EP; Nagarajah, R; Verma, V, 2007) |
| "Risperidone has been reported to decrease the reduction of MRI volume during the clinical course of schizophrenia." | 1.34 | Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. ( Hashioka, S; Kanba, S; Kato, T; Monji, A, 2007) |
| " Here we report the effects of acute and chronic administration of established and putative antipsychotics on these PPI deficits." | 1.34 | The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats. ( Feifel, D; Melendez, G; Priebe, K; Shilling, PD, 2007) |
| "Risperidone-treated animals showed a catalepsy-like phenotype, which differed to that of haloperidol-treated rats, indicating that processes other than the anticipated dopaminergic mechanisms are underlying this phenomenon." | 1.33 | Behavioural effects of chronic haloperidol and risperidone treatment in rats. ( Dedova, I; Duffy, L; Karl, T; Matsumoto, I; O'brien, E, 2006) |
| "Pretreatment with risperidone (0." | 1.32 | Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. ( Kato, S; Nisijima, K; Shioda, K; Takano, K; Yoshino, T, 2004) |
| " While typical antipsychotics are often switched to atypical agents when adverse effects become limiting, there is little preclinical information to support this strategy, both in terms of efficacy and side effects." | 1.32 | Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. ( Matsuoka, N; Mutoh, S; Shirakawa, K; Tada, M, 2004) |
| "Similarly to acute rat catalepsy, "early onset" vacuous chewing movements (VCMs) induced by subchronic treatment with antipsychotic have recently been proposed as a model of human extrapyramidal symptoms." | 1.32 | Haloperidol versus risperidone on rat "early onset" vacuous chewing. ( Bartholini, F; Casti, P; Casu, MA; Congeddu, E; Marchese, G; Pani, L; Ruiu, S; Tambaro, S, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (4.55) | 18.2507 |
| 2000's | 35 (26.52) | 29.6817 |
| 2010's | 79 (59.85) | 24.3611 |
| 2020's | 12 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Rowley, M | 1 |
| Bristow, LJ | 1 |
| Hutson, PH | 1 |
| Sekhar, KV | 1 |
| Rao, VS | 1 |
| Devambatla, RKV | 1 |
| Kumar, MM | 1 |
| Banerjee, A | 1 |
| Narayana, L | 1 |
| Raje, FA | 1 |
| Pisal, DV | 1 |
| Kadam, PA | 1 |
| Gullapalli, S | 1 |
| Kumar, H | 1 |
| More, SV | 1 |
| Bajpai, M | 1 |
| Sangana, RR | 1 |
| Jadhav, S | 1 |
| Gudi, GS | 1 |
| Khairatkar-Joshi, N | 1 |
| Merugu, RR | 1 |
| Voleti, SR | 1 |
| Gharat, LA | 1 |
| Zagórska, A | 1 |
| Kołaczkowski, M | 2 |
| Bucki, A | 1 |
| Siwek, A | 1 |
| Kazek, G | 1 |
| Satała, G | 1 |
| Bojarski, AJ | 1 |
| Partyka, A | 2 |
| Wesołowska, A | 2 |
| Pawłowski, M | 1 |
| Xiamuxi, H | 1 |
| Wang, Z | 1 |
| Li, J | 1 |
| Wang, Y | 3 |
| Wu, C | 1 |
| Yang, F | 1 |
| Jiang, X | 1 |
| Liu, Y | 2 |
| Zhao, Q | 1 |
| Chen, W | 2 |
| Zhang, J | 1 |
| Xie, Y | 1 |
| Hu, T | 1 |
| Xu, M | 1 |
| Guo, S | 1 |
| Akber Aisa, H | 1 |
| He, Y | 1 |
| Shen, J | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 2 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Li, Z | 2 |
| Cai, G | 1 |
| Fang, F | 1 |
| Fan, M | 1 |
| Lian, J | 1 |
| Qiu, Y | 1 |
| Xu, X | 1 |
| Lv, X | 1 |
| Li, Y | 2 |
| Zheng, R | 1 |
| Zhang, G | 1 |
| Liu, Z | 2 |
| Huang, Z | 1 |
| Zhang, L | 2 |
| Brandt, L | 1 |
| Montag, C | 1 |
| Bermpohl, F | 1 |
| Finck, A | 1 |
| Wieacker, E | 1 |
| Heinz, A | 1 |
| Gutwinski, S | 1 |
| Elnahas, EM | 2 |
| Abuelezz, SA | 1 |
| Mohamad, MI | 1 |
| Nabil, MM | 1 |
| Abdelraouf, SM | 1 |
| Bahaa, N | 1 |
| Hassan, GAM | 1 |
| Aboul-Fotouh, S | 2 |
| Mishra, A | 1 |
| Singla, R | 1 |
| Kumar, R | 1 |
| Sharma, A | 1 |
| Joshi, R | 1 |
| Sarma, P | 1 |
| Kaur, G | 1 |
| Prajapat, M | 1 |
| Bhatia, A | 1 |
| Medhi, B | 1 |
| Atia, AA | 1 |
| Ashour, RH | 1 |
| Zaki, MM | 1 |
| Rahman, KM | 1 |
| Ramadan, NM | 1 |
| Habib, MZ | 1 |
| Aboul-Ela, YM | 1 |
| Ebeid, MA | 1 |
| Tarek, M | 1 |
| Sadek, DR | 1 |
| Negm, EA | 1 |
| Abdelhakam, DA | 1 |
| Uniyal, A | 1 |
| Singh, R | 1 |
| Akhtar, A | 1 |
| Bansal, Y | 1 |
| Kuhad, A | 1 |
| Sah, SP | 1 |
| Okada, T | 2 |
| Shioda, K | 4 |
| Makiguchi, A | 1 |
| Suda, S | 1 |
| Horska, K | 2 |
| Kotolova, H | 1 |
| Karpisek, M | 1 |
| Babinska, Z | 1 |
| Hammer, T | 1 |
| Prochazka, J | 1 |
| Stark, T | 1 |
| Micale, V | 2 |
| Ruda-Kucerova, J | 2 |
| Kucera, J | 1 |
| Hruska, P | 1 |
| Kuruczova, D | 1 |
| Bienertova-Vasku, J | 1 |
| Cope, ZA | 1 |
| Kenton, JA | 1 |
| Minassian, A | 1 |
| Martin, MV | 1 |
| Perry, W | 1 |
| Bundgaard, C | 1 |
| Arnt, J | 2 |
| van Enkhuizen, J | 1 |
| Geyer, MA | 2 |
| Young, JW | 2 |
| Mihai, DP | 1 |
| Ungurianu, A | 1 |
| Ciotu, CI | 1 |
| Fischer, MJM | 1 |
| Olaru, OT | 1 |
| Nitulescu, GM | 1 |
| Andrei, C | 1 |
| Zbarcea, CE | 1 |
| Zanfirescu, A | 1 |
| Seremet, OC | 1 |
| Chirita, C | 1 |
| Negres, S | 1 |
| Sun, WW | 1 |
| Li, LY | 1 |
| Huang, XF | 1 |
| Shi, YC | 1 |
| Yang, HQ | 1 |
| Song, ZY | 1 |
| Lin, S | 1 |
| Farrelly, L | 2 |
| Rosato-Siri, MV | 1 |
| Föcking, M | 2 |
| Codagnone, M | 1 |
| Reines, A | 1 |
| Dicker, P | 2 |
| Wynne, K | 2 |
| Farrell, M | 1 |
| Cannon, M | 2 |
| Cagney, G | 2 |
| Pasquini, JM | 1 |
| Cotter, DR | 2 |
| Hara, Y | 1 |
| Ago, Y | 1 |
| Taruta, A | 1 |
| Hasebe, S | 1 |
| Kawase, H | 1 |
| Tanabe, W | 1 |
| Tsukada, S | 1 |
| Nakazawa, T | 1 |
| Hashimoto, H | 3 |
| Matsuda, T | 1 |
| Takuma, K | 1 |
| Xue, F | 1 |
| Chen, YC | 1 |
| Zhou, CH | 1 |
| Cai, M | 1 |
| Yan, WJ | 1 |
| Wu, R | 1 |
| Wang, HN | 1 |
| Peng, ZW | 1 |
| Ben-Azu, B | 2 |
| Omogbiya, IA | 1 |
| Aderibigbe, AO | 2 |
| Umukoro, S | 2 |
| Ajayi, AM | 2 |
| Iwalewa, EO | 2 |
| Watremez, W | 1 |
| Jackson, J | 1 |
| Almari, B | 1 |
| McLean, SL | 1 |
| Grayson, B | 2 |
| Neill, JC | 2 |
| Fischer, N | 1 |
| Allouche, A | 1 |
| Koziel, V | 1 |
| Pillot, T | 1 |
| Harte, MK | 1 |
| Papp, M | 1 |
| Gruca, P | 1 |
| Lason-Tyburkiewicz, M | 1 |
| Litwa, E | 1 |
| Niemczyk, M | 1 |
| Tota-Glowczyk, K | 1 |
| Faron-Gorecka, A | 1 |
| Kusmider, M | 1 |
| Solich, J | 1 |
| Szlachta, M | 1 |
| Willner, P | 1 |
| Eneni, AO | 1 |
| Koh, MT | 1 |
| Ahrens, PS | 1 |
| Gallagher, M | 1 |
| Dean, B | 1 |
| Gibbons, A | 1 |
| Gogos, A | 1 |
| Udawela, M | 1 |
| Thomas, E | 1 |
| Scarr, E | 1 |
| Takahashi, K | 1 |
| Nakagawasai, O | 1 |
| Sakuma, W | 1 |
| Nemoto, W | 1 |
| Odaira, T | 1 |
| Lin, JR | 1 |
| Onogi, H | 1 |
| Srivastava, LK | 1 |
| Tan-No, K | 1 |
| Casquero-Veiga, M | 1 |
| García-García, D | 1 |
| MacDowell, KS | 2 |
| Pérez-Caballero, L | 1 |
| Torres-Sánchez, S | 1 |
| Fraguas, D | 1 |
| Berrocoso, E | 1 |
| Leza, JC | 2 |
| Arango, C | 2 |
| Desco, M | 1 |
| Soto-Montenegro, ML | 1 |
| Roman, A | 1 |
| Kuśmierczyk, J | 1 |
| Klimek, E | 1 |
| Rogóż, Z | 3 |
| Nalepa, I | 1 |
| Kabziński, M | 1 |
| Sadaj, W | 1 |
| Rachwalska, P | 1 |
| Gądek-Michalska, A | 1 |
| Sotoyama, H | 2 |
| Namba, H | 2 |
| Chiken, S | 1 |
| Nambu, A | 1 |
| Nawa, H | 2 |
| Tsuchie, K | 1 |
| Miyaoka, T | 1 |
| Furuya, M | 1 |
| Liaury, K | 1 |
| Ieda, M | 1 |
| Wake, R | 1 |
| Horiguchi, J | 1 |
| Takechi, M | 1 |
| Krishnamurthy, S | 2 |
| Garabadu, D | 1 |
| Joy, KP | 1 |
| Yan, BC | 1 |
| Park, JH | 2 |
| Ahn, JH | 1 |
| Kim, IH | 1 |
| Park, OK | 1 |
| Lee, JC | 2 |
| Yoo, KY | 1 |
| Choi, JH | 1 |
| Lee, CH | 1 |
| Hwang, IK | 1 |
| Her, S | 1 |
| Kim, JS | 1 |
| Shin, HC | 1 |
| Cho, JH | 1 |
| Kim, YM | 1 |
| Kwon, SH | 1 |
| Won, MH | 1 |
| Santoro, ML | 2 |
| Ota, VK | 2 |
| Stilhano, RS | 1 |
| Silva, PN | 1 |
| Santos, CM | 2 |
| Diana, MC | 2 |
| Gadelha, A | 1 |
| Bressan, RA | 2 |
| Melaragno, MI | 1 |
| Han, SW | 1 |
| Abílio, VC | 3 |
| Belangero, SI | 2 |
| Amodeo, DA | 1 |
| Jones, JH | 1 |
| Sweeney, JA | 1 |
| Ragozzino, ME | 1 |
| Huang, YR | 1 |
| Pai, CW | 1 |
| Cheng, KH | 1 |
| Kuo, WI | 1 |
| Chen, MW | 1 |
| Chang, KW | 1 |
| Doorduin, J | 1 |
| de Vries, EF | 1 |
| Dierckx, RA | 1 |
| Klein, HC | 1 |
| Karamihalev, S | 1 |
| Prickaerts, J | 1 |
| van Goethem, NP | 1 |
| O'Sullivan, D | 1 |
| Green, L | 1 |
| Stone, S | 1 |
| Zareie, P | 1 |
| Kharkrang, M | 1 |
| Fong, D | 1 |
| Connor, B | 1 |
| La Flamme, AC | 1 |
| Citraro, R | 1 |
| Leo, A | 1 |
| Aiello, R | 1 |
| Pugliese, M | 1 |
| Russo, E | 1 |
| De Sarro, G | 1 |
| Heller, HC | 1 |
| Salehi, A | 1 |
| Chuluun, B | 1 |
| Das, D | 1 |
| Lin, B | 1 |
| Moghadam, S | 1 |
| Garner, CC | 1 |
| Colas, D | 1 |
| Piontkewitz, Y | 3 |
| English, J | 1 |
| Bent, S | 1 |
| Hendren, RL | 1 |
| Torres-Lista, V | 1 |
| López-Pousa, S | 1 |
| Giménez-Llort, L | 1 |
| Dang, R | 1 |
| Jiang, P | 2 |
| Cai, H | 1 |
| Li, H | 1 |
| Guo, R | 1 |
| Wu, Y | 1 |
| Zhu, W | 1 |
| He, X | 1 |
| Xu, P | 2 |
| Mas, S | 1 |
| Gassó, P | 1 |
| Boloc, D | 1 |
| Rodriguez, N | 1 |
| Mármol, F | 1 |
| Sánchez, J | 1 |
| Bernardo, M | 1 |
| Lafuente, A | 1 |
| Wlodarczyk, BJ | 1 |
| Ogle, K | 1 |
| Lin, LY | 1 |
| Bialer, M | 1 |
| Finnell, RH | 1 |
| Xavier, G | 1 |
| Spindola, LN | 1 |
| Moretti, PN | 1 |
| Patrich, E | 1 |
| Peretz, A | 1 |
| Weiner, I | 2 |
| Attali, B | 1 |
| Cai, HL | 1 |
| Tan, QY | 1 |
| Dang, RL | 1 |
| Xue, Y | 1 |
| Tang, MM | 1 |
| Deng, Y | 1 |
| Li, HD | 1 |
| Yao, JK | 1 |
| Vaisburd, S | 1 |
| Shemer, Z | 1 |
| Yeheskel, A | 1 |
| Giladi, E | 1 |
| Gozes, I | 1 |
| Kiss, B | 1 |
| Gyertyán, I | 1 |
| Ferguson, P | 1 |
| Adham, N | 1 |
| Ihalainen, J | 1 |
| Savolainen, K | 1 |
| Tanila, H | 1 |
| Forsberg, MM | 1 |
| Wasik, A | 1 |
| Jastrzębska-Więsek, M | 1 |
| Mierzejewski, P | 1 |
| Bieńkowski, P | 1 |
| Vardigan, JD | 1 |
| Lange, HS | 1 |
| Tye, SJ | 1 |
| Fox, SV | 1 |
| Smith, SM | 1 |
| Uslaner, JM | 1 |
| El-Sayed El-Sisi, A | 1 |
| Sokkar, SS | 1 |
| El-Sayed El-Sayad, M | 1 |
| Sayed Ramadan, E | 1 |
| Osman, EY | 1 |
| Marcus, MM | 1 |
| Björkholm, C | 1 |
| Malmerfelt, A | 1 |
| Möller, A | 1 |
| Påhlsson, N | 1 |
| Konradsson-Geuken, Å | 1 |
| Feltmann, K | 1 |
| Jardemark, K | 1 |
| Schilström, B | 1 |
| Svensson, TH | 1 |
| Hatalova, H | 1 |
| Radostova, D | 1 |
| Pistikova, A | 1 |
| Vales, K | 1 |
| Stuchlik, A | 1 |
| da Silva Araújo, T | 1 |
| Maia Chaves Filho, AJ | 1 |
| Monte, AS | 1 |
| Isabelle de Góis Queiroz, A | 1 |
| Cordeiro, RC | 1 |
| de Jesus Souza Machado, M | 1 |
| de Freitas Lima, R | 1 |
| Freitas de Lucena, D | 1 |
| Maes, M | 1 |
| Macêdo, D | 1 |
| Singh, KP | 1 |
| Singh, MK | 1 |
| Wu, L | 1 |
| Feng, X | 1 |
| Li, T | 1 |
| Sun, B | 1 |
| Khan, MZ | 1 |
| He, L | 1 |
| Liu, YP | 1 |
| Yang, YY | 1 |
| Wan, FJ | 1 |
| Tung, CS | 1 |
| Schwartzer, JJ | 1 |
| Connor, DF | 2 |
| Morrison, RL | 1 |
| Ricci, LA | 2 |
| Melloni, RH | 2 |
| Nisijima, K | 4 |
| Yoshino, T | 4 |
| Kuboshima, K | 1 |
| Iwamura, T | 1 |
| Yui, K | 1 |
| Kato, S | 3 |
| Richtand, NM | 3 |
| McNamara, RK | 3 |
| Dhir, A | 1 |
| Kulkarni, SK | 1 |
| Ehrlichman, RS | 2 |
| Gandal, MJ | 2 |
| Maxwell, CR | 1 |
| Lazarewicz, MT | 1 |
| Finkel, LH | 1 |
| Contreras, D | 1 |
| Turetsky, BI | 1 |
| Siegel, SJ | 3 |
| Li, M | 1 |
| He, W | 1 |
| Mead, A | 1 |
| Marston, HM | 1 |
| Martin, FD | 1 |
| Serpa, KA | 1 |
| Moore, CL | 1 |
| Wong, EH | 1 |
| Gold, L | 1 |
| Meltzer, LT | 1 |
| Azar, MR | 1 |
| Shahid, M | 1 |
| van der Staay, FJ | 1 |
| Pouzet, B | 1 |
| Mahieu, M | 1 |
| Nordquist, RE | 1 |
| Schuurman, T | 1 |
| Jenkins, TA | 2 |
| Elliott, JJ | 1 |
| Ardis, TC | 1 |
| Cahir, M | 1 |
| Reynolds, GP | 2 |
| Bell, R | 1 |
| Cooper, SJ | 1 |
| Zhang, XR | 1 |
| Zhang, ZJ | 1 |
| Cheng, WR | 1 |
| Arad, M | 1 |
| Sun, F | 1 |
| Su, Z | 1 |
| Sui, C | 1 |
| Zhang, C | 1 |
| Yuan, L | 1 |
| Meng, Q | 1 |
| Teng, L | 1 |
| Chatterjee, M | 1 |
| Ganguly, S | 1 |
| Srivastava, M | 1 |
| Palit, G | 1 |
| Wadenberg, ML | 1 |
| Fjällström, AK | 1 |
| Federley, M | 1 |
| Persson, P | 1 |
| Stenqvist, P | 1 |
| Chadman, KK | 2 |
| Jandacek, R | 1 |
| Rider, T | 1 |
| Tso, P | 1 |
| Saxena, B | 1 |
| Singh, S | 1 |
| Lauressergues, E | 1 |
| Martin, F | 1 |
| Helleboid, A | 1 |
| Bouchaert, E | 1 |
| Cussac, D | 1 |
| Bordet, R | 1 |
| Hum, D | 1 |
| Luc, G | 1 |
| Majd, Z | 1 |
| Staels, B | 1 |
| Duriez, P | 1 |
| Ortega-Alvaro, A | 1 |
| Aracil-Fernández, A | 1 |
| García-Gutiérrez, MS | 1 |
| Navarrete, F | 1 |
| Manzanares, J | 1 |
| Ahlbrand, R | 2 |
| Horn, P | 1 |
| Stanford, K | 1 |
| Bronson, SL | 2 |
| Hannah-Poquette, C | 1 |
| Anderson, GW | 1 |
| Flaisher-Grinberg, S | 1 |
| Wang, J | 1 |
| Meinerding, TM | 1 |
| Einat, H | 1 |
| Adeneye, AA | 1 |
| Agbaje, EO | 1 |
| Olagunju, JA | 1 |
| Roenker, NL | 1 |
| Gudelsky, G | 1 |
| Kern, JR | 1 |
| Waterman, H | 1 |
| Zheng, Y | 1 |
| Iwakura, Y | 1 |
| Mizuno, M | 1 |
| Aizawa, M | 1 |
| Shcherbakova, K | 1 |
| Wang, R | 1 |
| García-Bueno, B | 1 |
| Madrigal, JL | 1 |
| Parellada, M | 1 |
| Micó, JA | 1 |
| Guariglia, SR | 1 |
| Yoo, JH | 1 |
| Chindo, BA | 1 |
| Adzu, B | 1 |
| Yahaya, TA | 1 |
| Gamaniel, KS | 1 |
| Stojković, T | 1 |
| Radonjić, NV | 1 |
| Velimirović, M | 1 |
| Jevtić, G | 1 |
| Popović, V | 1 |
| Doknić, M | 1 |
| Petronijević, ND | 1 |
| Sisti, J | 1 |
| Klook, K | 1 |
| Ortinski, PI | 1 |
| Leitman, V | 1 |
| Liang, Y | 2 |
| Thieu, T | 1 |
| Anderson, R | 1 |
| Pierce, RC | 1 |
| Jonak, G | 1 |
| Gur, RE | 1 |
| Carlson, G | 1 |
| Olszewski, RT | 1 |
| Janczura, KJ | 1 |
| Ball, SR | 1 |
| Madore, JC | 1 |
| Lavin, KM | 1 |
| Lee, MJ | 1 |
| Der, EK | 1 |
| Hark, TJ | 1 |
| Farago, PR | 1 |
| Profaci, CP | 1 |
| Bzdega, T | 1 |
| Neale, JH | 1 |
| Kasai, M | 1 |
| Wilson, CA | 1 |
| Terry, AV | 2 |
| Castellano, O | 1 |
| Arji, M | 1 |
| Sancho, C | 1 |
| Carro, J | 1 |
| Riolobos, AS | 1 |
| Molina, V | 1 |
| Gómez-Nieto, R | 1 |
| de Anchieta de Castro E Horta, J | 1 |
| Herrero-Turrión, MJ | 1 |
| López, DE | 1 |
| Lai, M | 1 |
| Zhu, H | 1 |
| Zhou, X | 1 |
| Liu, H | 2 |
| Zhang, F | 1 |
| Zhou, W | 1 |
| McIntosh, AL | 1 |
| Ballard, TM | 1 |
| Steward, LJ | 1 |
| Moran, PM | 1 |
| Fone, KC | 1 |
| Carvalho, RC | 1 |
| Silva, RH | 1 |
| Barbosa, PN | 1 |
| Frussa-Filho, R | 1 |
| Ingman, K | 1 |
| Honkanen, A | 1 |
| Hyytiä, P | 1 |
| Huttunen, MO | 1 |
| Korpi, ER | 1 |
| Goudie, AJ | 1 |
| Halford, JC | 1 |
| Cooper, GD | 1 |
| Dovey, T | 1 |
| Pickavance, LC | 1 |
| Wilding, JP | 1 |
| Shintani, N | 2 |
| Tanaka, K | 2 |
| Baba, A | 2 |
| Marchese, G | 1 |
| Bartholini, F | 1 |
| Casu, MA | 1 |
| Ruiu, S | 1 |
| Casti, P | 1 |
| Congeddu, E | 1 |
| Tambaro, S | 1 |
| Pani, L | 1 |
| Takano, K | 1 |
| Tada, M | 1 |
| Shirakawa, K | 1 |
| Matsuoka, N | 1 |
| Mutoh, S | 1 |
| Matsushita, M | 1 |
| Egashira, N | 1 |
| Harada, S | 1 |
| Okuno, R | 1 |
| Mishima, K | 1 |
| Iwasaki, K | 1 |
| Nishimura, R | 1 |
| Fujiwara, M | 1 |
| Pillai, A | 1 |
| Parikh, V | 1 |
| Mahadik, SP | 1 |
| Karl, T | 1 |
| Duffy, L | 1 |
| O'brien, E | 1 |
| Matsumoto, I | 1 |
| Dedova, I | 1 |
| Lim, EP | 1 |
| Verma, V | 2 |
| Nagarajah, R | 1 |
| Dawe, GS | 2 |
| Morrison, R | 1 |
| Wang, D | 1 |
| Noda, Y | 2 |
| Zhou, Y | 1 |
| Nitta, A | 1 |
| Furukawa, H | 1 |
| Nabeshima, T | 2 |
| Kato, T | 1 |
| Monji, A | 1 |
| Hashioka, S | 1 |
| Kanba, S | 1 |
| Hashimoto, R | 1 |
| Chiba, S | 1 |
| Hattori, S | 1 |
| Nakajima, M | 1 |
| Kawagishi, N | 1 |
| Nemoto, K | 1 |
| Mori, T | 1 |
| Ohnishi, T | 1 |
| Noguchi, H | 1 |
| Hori, H | 1 |
| Suzuki, T | 1 |
| Iwata, N | 1 |
| Ozaki, N | 1 |
| Nakabayashi, T | 1 |
| Saitoh, O | 1 |
| Kosuga, A | 1 |
| Tatsumi, M | 1 |
| Kamijima, K | 1 |
| Weinberger, DR | 1 |
| Kunugi, H | 1 |
| Didriksen, M | 1 |
| Skarsfeldt, T | 1 |
| Amitai, N | 1 |
| Semenova, S | 1 |
| Markou, A | 1 |
| Feifel, D | 1 |
| Melendez, G | 1 |
| Priebe, K | 1 |
| Shilling, PD | 1 |
| Rabin, C | 1 |
| Budhian, A | 1 |
| Metzger, KL | 1 |
| Majewski-Tiedeken, C | 1 |
| Winey, KI | 1 |
| Muehlmann, AM | 1 |
| Brown, BD | 1 |
| Devine, DP | 1 |
| Zuo, J | 1 |
| Ouyang, X | 1 |
| Hao, Y | 1 |
| Xu, L | 1 |
| Lu, XH | 1 |
| Tan, CH | 1 |
| Ong, WY | 1 |
| Grigoryan, GA | 1 |
| Jones, CA | 1 |
| Stolzberg, D | 1 |
| Salvi, R | 1 |
| Gross, KW | 1 |
| Ratty, AK | 1 |
| Abekawa, T | 1 |
| Ito, K | 1 |
| Nakagawa, S | 1 |
| Nakato, Y | 1 |
| Koyama, T | 1 |
| Grant, S | 1 |
| Fitton, A | 1 |
| Kapur, S | 1 |
| Remington, G | 1 |
| Megens, AA | 1 |
| Kennis, LE | 1 |
| Allen, SM | 1 |
| Freeman, JN | 1 |
| Davis, WM | 1 |
| Prinssen, EP | 1 |
| Kleven, MS | 1 |
| Koek, W | 1 |
| Ishiguro, T | 1 |
| Andersson, C | 1 |
| Hamer, RM | 1 |
| Lawler, CP | 1 |
| Mailman, RB | 1 |
| Lieberman, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Video Assisted Speech Technology to Enhance Functional Language Abilities in Individuals With Autism Spectrum Disorder[NCT04764539] | 6 participants (Actual) | Interventional | 2019-12-01 | Completed | |||
| Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva[NCT00395499] | 19 participants | Observational | 2001-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in % of correct phonemes in each attempted stimulus (NCT04764539)
Timeframe: Seven weeks--each subject participated in the study twice a week over a 7-week period for a total of 14 sessions. The first and last sessions (session #1 and session #14) were reserved for pre-test and post-test language sample collection and assessment.
| Intervention | percentage of correct phonemes (Mean) |
|---|---|
| Stimuli Administered Via 2D Format on an iPad Pro | 19.75 |
| Stimuli Administered in 3D Format Via VR Goggles and Bone Conduction Headphones | 16.24 |
"Participants (aged 4 to 8 years) were given a pre- and post-test 15-minute language sample. MLU was calculated for tests and gain from pre-test to post-test was compared.~NOTE: This measure is calculated based on a change in the number of morphemes per utterance during pre-test and post-test language samples. During a five-minute period, two licensed speech-language pathologists (SLP) observed a parent interacting and talking with their child. Parents Both SLPs transcribed the subjects' speech and calculated a mean length of utterance (MLU) for each subject. MLU was calculated by determining how many bound and free morphemes were included within every spoken utterance produced by a subject. The total number of morphemes produced within the 5-minute period were then divided by total number of utterances, which then produced the MLU for each subject. This procedure was use for determining MLU in both the pre- and post-testing procedures." (NCT04764539)
Timeframe: Seven weeks--each subject participated in the study twice a week over a 7-week period for a total of 14 sessions. The first and last sessions (session #1 and session #14) were reserved for pre-test and post-test language sample collection and assessment.
| Intervention | Morphemes per utterance (Mean) |
|---|---|
| Stimuli Administered Via 2D Format on an iPad Pro | 0.5387 |
| Stimuli Administered in 3D Format Via VR Goggles and Bone Conduction Headphones | 0.2987 |
"15-minute pre- and post-testing was performed using speech recognition software and transcribed by a licensed speech pathologist. Differences pre and post intervention were compared across group and within groups.~NOTE: During our assessment, we used Google's native closed captioning function (a tool which uses machine learning to recognize and transcribe speech) and a third party app, Tactiq Pins, which allows users to keep a transcript of all speaker utterances during a call. We compared our video to the Tactiq Pin transcripts in order to measure any change in the amount of accurately transcribed spoken words between pre-test and post-test language samples. Specific transcription results for each group can be found in the data tables provided." (NCT04764539)
Timeframe: Seven weeks--each subject participated in the study twice a week over a 7-week period for a total of 14 sessions. The first and last sessions (session #1 and session #14) were reserved for pre-test and post-test language sample collection and assessment.
| Intervention | % of correctly transcribed words (Mean) |
|---|---|
| Stimuli Administered Via 2D Format on an iPad Pro | 1.388 |
| Stimuli Administered in 3D Format Via VR Goggles and Bone Conduction Headphones | 0 |
A type-token ratio measures the total number of unique words in a given segment of language. (NCT04764539)
Timeframe: Seven weeks--each subject participated in the study twice a week over a 7-week period for a total of 14 sessions. The first and last sessions (session #1 and session #14) were reserved for pre-test and post-test language sample collection and assessment.
| Intervention | number of unique words in a segment (Mean) |
|---|---|
| Stimuli Administered Via 2D Format on an iPad Pro | 30.158 |
| Stimuli Administered in 3D Format Via VR Goggles and Bone Conduction Headphones | 22.26 |
The change in response rate measures any significant differences in how often children responded to pre- and post-testing stimuli after having received treatment between the iPad Pro and VR goggles groups. A response is considered a verbal or non-verbal reaction (e.g., eye contact, gestures, vocalizations) to the stimuli presented during the therapy sessions. Higher response rates indicate better engagement and responsiveness to the treatment. The change in response rate is calculated as the value at the post-test time point minus the value at the pre-test time point, with positive numbers representing increases and negative numbers representing decreases in response rate. (NCT04764539)
Timeframe: Seven weeks--each subject participated in the study twice a week over a 7-week period for a total of 14 sessions. The first and last sessions (session #1 and session #14) were reserved for pre-test and post-test language sample collection and assessment.
| Intervention | Number of responses (Mean) |
|---|---|
| Stimuli Administered Via 2D Format on an iPad Pro | 5.67 |
| Stimuli Administered in 3D Format Via VR Goggles and Bone Conduction Headphones | 3.33 |
"Parent observations -- perceptions of changes in their children's motor-speech, behavioral, and social communication skills after having participated in the study~Scale title: Net Positive Changes Score Maximum possible value: 18 Minimum possible value: -2 Higher score is better." (NCT04764539)
Timeframe: Seven weeks--each subject participated in the study twice a week over a 7-week period for a total of 14 sessions. The first and last sessions (session #1 and session #14) were reserved for pre-test and post-test language sample collection and assessment.
| Intervention | Score on a scale (Mean) |
|---|---|
| Parents of Participants, Who Received VAST Stimuli Via a 2D Format on an iPad Pro | 11 |
| Parents of Participants, Who Received VAST Stimuli Through VR Goggles and Bone Conduction Headphones | 9.67 |
8 reviews available for risperidone and Disease Models, Animal
| Article | Year |
|---|---|
Current and novel approaches to the drug treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Cholinergic Agonists; Disease Models, Animal; Dopamine Antagonists; E | 2001 |
The effect of second-generation antipsychotic withdrawal on the occurrence of vacuous chewing movements in animal models: A review.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Mastication; Risperidone; Substance Withdrawa | 2022 |
Complementary and alternative treatments for autism part 1: evidence-supported treatments.
Topics: Acetylcysteine; Animals; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Complementary Therap | 2015 |
Serotonin and dopamine interactions in psychosis prevention.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Antagoni | 2008 |
New directions in the treatment of autism spectrum disorders from animal model research.
Topics: Adolescent; Adolescent Behavior; Animals; Antipsychotic Agents; Aripiprazole; Brain; Central Nervous | 2012 |
Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia.
Topics: Absorption; Adult; Aged; Aging; Animals; Antipsychotic Agents; Central Nervous System; Cross-Over St | 1994 |
Serotonin-dopamine interaction and its relevance to schizophrenia.
Topics: Animals; Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Disease Models, Animal; Dopamine | 1996 |
Risperidone and related 5HT2/D2 antagonists: a new type of antipsychotic agent?
Topics: Animals; Disease Models, Animal; Humans; Molecular Structure; Risperidone; Schizophrenia | 1996 |
1 trial available for risperidone and Disease Models, Animal
| Article | Year |
|---|---|
Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia.
Topics: Absorption; Adult; Aged; Aging; Animals; Antipsychotic Agents; Central Nervous System; Cross-Over St | 1994 |
124 other studies available for risperidone and Disease Models, Animal
| Article | Year |
|---|---|
Synthesis and preliminary pharmacological evaluation of N-2-(4-(4-(2-substitutedthiazol-4-yl) piperazin-1-yl)-2-oxoethyl)acetamides as novel atypical antipsychotic agents.
Topics: Acetamides; Animals; Antipsychotic Agents; Combinatorial Chemistry Techniques; Disease Models, Anima | 2008 |
Discovery of benzo[d]imidazo[5,1-b]thiazole as a new class of phosphodiesterase 10A inhibitors.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dizocilpine Maleate; Drug Evaluation, Preclin | 2013 |
Structure-activity relationships and molecular studies of novel arylpiperazinylalkyl purine-2,4-diones and purine-2,4,8-triones with antidepressant and anxiolytic-like activity.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Binding Sites; Disease Models, Animal; Models, | 2015 |
Synthesis and biological investigation of tetrahydropyridopyrimidinone derivatives as potential multireceptor atypical antipsychotics.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Disease Models, Animal; Dogs; Half-Life; | 2017 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Discovery of Novel and Potent
Topics: Action Potentials; Allosteric Regulation; Animals; Antidepressive Agents; Binding Sites; Cell Surviv | 2021 |
Novel role of peroxisome proliferator activated receptor-α in valproic acid rat model of autism: Mechanistic study of risperidone and metformin monotherapy versus combination.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Fema | 2022 |
Granulocyte Colony-Stimulating Factor Improved Core Symptoms of Autism Spectrum Disorder via Modulating Glutamatergic Receptors in the Prefrontal Cortex and Hippocampus of Rat Brains.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Autism Spectrum Disorder; Brain; | 2022 |
The comparative effectiveness of metformin and risperidone in a rat model of valproic acid-induced autism, Potential role for enhanced autophagy.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Autophagy; Disease Models, Animal; Female; Hum | 2023 |
Risperidone impedes glutamate excitotoxicity in a valproic acid rat model of autism: Role of ADAR2 in AMPA GluA2 RNA editing.
Topics: Adenosine Deaminase; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Autism Spect | 2023 |
Co-treatment of piracetam with risperidone rescued extinction deficits in experimental paradigms of post-traumatic stress disorder by restoring the physiological alterations in cortex and hippocampus.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Corticosterone; Disease Models, Animal; Drug Synerg | 2019 |
Risperidone and 5-HT2A Receptor Antagonists Attenuate and Reverse Cocaine-Induced Hyperthermia in Rats.
Topics: Animals; Benzazepines; Cocaine; Disease Models, Animal; Dopamine Antagonists; Dopamine Uptake Inhibi | 2020 |
Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Female; Haloperidol; Lipid Metabolism; Male; | 2020 |
Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Disease Models, Animal; Female; Haloperidol; Intra-Ab | 2021 |
Chronic antipsychotic treatment exerts limited effects on the mania-like behavior of dopamine transporter knockdown mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Bipolar Disorder; Dibenzocycloheptenes; Disease Mod | 2021 |
Effects of Venlafaxine, Risperidone and Febuxostat on Cuprizone-Induced Demyelination, Behavioral Deficits and Oxidative Stress.
Topics: Animals; Corpus Callosum; Cuprizone; Disease Models, Animal; Drug Evaluation, Preclinical; Febuxosta | 2021 |
The central mechanism of risperidone-induced hyperprolactinemia.
Topics: Animals; Antipsychotic Agents; Arcuate Nucleus of Hypothalamus; Disease Models, Animal; Female; Hype | 2017 |
The Effects of Prenatal Iron Deficiency and Risperidone Treatment on the Rat Frontal Cortex: A Proteomic Analysis.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Female; Frontal Lobe; Iron; | 2017 |
Risperidone and aripiprazole alleviate prenatal valproic acid-induced abnormalities in behaviors and dendritic spine density in mice.
Topics: Animals; Aripiprazole; Autism Spectrum Disorder; Dendritic Spines; Disease Models, Animal; Dopamine; | 2017 |
Risperidone ameliorates cognitive deficits, promotes hippocampal proliferation, and enhances Notch signaling in a murine model of schizophrenia.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Hippocampus; Male; Mice; Mice, Inbred C57BL; R | 2017 |
Doxycycline prevents and reverses schizophrenic-like behaviors induced by ketamine in mice via modulation of oxidative, nitrergic and cholinergic pathways.
Topics: Acetylcholinesterase; Animals; Antipsychotic Agents; Catalase; Disease Models, Animal; Doxycycline; | 2018 |
Stabilized Low-n Amyloid-β Oligomers Induce Robust Novel Object Recognition Deficits Associated with Inflammatory, Synaptic, and GABAergic Dysfunction in the Rat.
Topics: Amyloid beta-Peptides; Animals; Brain; Cognition; Disease Models, Animal; Donepezil; Female; gamma-A | 2018 |
Effects on brain-derived neurotrophic factor signalling of chronic mild stress, chronic risperidone and acute intracranial dopamine receptor challenges.
Topics: Animals; Antipsychotic Agents; Benzazepines; Brain-Derived Neurotrophic Factor; Disease Models, Anim | 2018 |
Involvement of GABAergic, BDNF and Nox-2 mechanisms in the prevention and reversal of ketamine-induced schizophrenia-like behavior by morin in mice.
Topics: Animals; Antioxidants; Behavioral Symptoms; Brain; Brain-Derived Neurotrophic Factor; Catalase; Dise | 2018 |
A greater tendency for representation mediated learning in a ketamine mouse model of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Central Nervous System Stimulants; Delusions; Disease Mo | 2018 |
Studies on Prostaglandin-Endoperoxide Synthase 1: Lower Levels in Schizophrenia and After Treatment with Antipsychotic Drugs in Conjunction with Aspirin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aspirin; Bipolar Disorder; B | 2018 |
Prenatal treatment with methylazoxymethanol acetate as a neurodevelopmental disruption model of schizophrenia in mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Clozapine; Disease Models, Animal; Fe | 2019 |
Risperidone administered during adolescence induced metabolic, anatomical and inflammatory/oxidative changes in adult brain: A PET and MRI study in the maternal immune stimulation animal model.
Topics: Animals; Antipsychotic Agents; Brain; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Mag | 2019 |
Effects of co-administration of fluoxetine and risperidone on properties of peritoneal and pleural macrophages in rats subjected to the forced swimming test.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Arginase; Behavior, Animal; | 2012 |
Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsychotic A | 2012 |
Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice.
Topics: Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Dextroamphetamine; Disease Models, An | 2012 |
Exposure to the cytokine EGF leads to abnormal hyperactivity of pallidal GABA neurons: implications for schizophrenia and its modeling.
Topics: Action Potentials; Animals; Animals, Newborn; Antipsychotic Agents; Disease Models, Animal; Electroe | 2013 |
The effects of antipsychotics on behavioral abnormalities of the Gunn rat (unconjugated hyperbilirubinemia rat), a rat model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Haloperidol; Hyperbilirubinemia | 2013 |
Risperidone ameliorates post-traumatic stress disorder-like symptoms in modified stress re-stress model.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Brain; Corticosterone; Dise | 2013 |
Neuroprotection of posttreatment with risperidone, an atypical antipsychotic drug, in rat and gerbil models of ischemic stroke and the maintenance of antioxidants in a gerbil model of ischemic stroke.
Topics: Animals; Antioxidants; Blotting, Western; Brain Ischemia; Disease Models, Animal; Gerbillinae; Immun | 2014 |
Effect of antipsychotic drugs on gene expression in the prefrontal cortex and nucleus accumbens in the spontaneously hypertensive rat (SHR).
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; DNA Methylation; Gene Expression; | 2014 |
Risperidone and the 5-HT2A receptor antagonist M100907 improve probabilistic reversal learning in BTBR T + tf/J mice.
Topics: Animals; Antipsychotic Agents; Autistic Disorder; Disease Models, Animal; Fluorobenzenes; Male; Mice | 2014 |
Dopamine D(2)/D(3) receptor binding of [(123)I]epidepride in risperidone-treatment chronic MK-801-induced rat schizophrenia model using nanoSPECT/CT neuroimaging.
Topics: Animals; Benzamides; Chronic Disease; Disease Models, Animal; Dizocilpine Maleate; Male; Multimodal | 2014 |
P-glycoprotein activity in the blood-brain barrier is affected by virus-induced neuroinflammation and antipsychotic treatment.
Topics: Animals; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; Blood-Brain Barrier; B | 2014 |
Donepezil and the alpha-7 agonist PHA 568487, but not risperidone, ameliorate spatial memory deficits in a subchronic MK-801 mouse model of cognitive impairment in schizophrenia.
Topics: Acetylcholinesterase; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Aza Co | 2014 |
Treatment with the antipsychotic agent, risperidone, reduces disease severity in experimental autoimmune encephalomyelitis.
Topics: Animals; Antigens; Antipsychotic Agents; Cell Survival; Cytokines; Disease Models, Animal; Dose-Resp | 2014 |
Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Disease Models, Animal; Epi | 2015 |
Nest building is impaired in the Ts65Dn mouse model of Down syndrome and rescued by blocking 5HT2a receptors.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Down Syndrome; Gene Expression; Mice; Nesting | 2014 |
Maternal immune activation induces changes in myelin and metabolic proteins, some of which can be prevented with risperidone in adolescence.
Topics: Aging; Animals; Antipsychotic Agents; Disease Models, Animal; Female; Male; Myelin Sheath; Prefronta | 2015 |
Marble-burying is enhanced in 3xTg-AD mice, can be reversed by risperidone and it is modulable by handling.
Topics: Alzheimer Disease; Animals; Antipsychotic Agents; Anxiety; Behavior, Animal; Disease Models, Animal; | 2015 |
Vitamin D deficiency exacerbates atypical antipsychotic-induced metabolic side effects in rats: involvement of the INSIG/SREBP pathway.
Topics: Animals; Antipsychotic Agents; Body Weight; Clozapine; Disease Models, Animal; Eating; Glucose Intol | 2015 |
Network analysis of gene expression in mice provides new evidence of involvement of the mTOR pathway in antipsychotic-induced extrapyramidal symptoms.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Animal; Blotting, Western; Disease | 2016 |
Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice.
Topics: Amides; Animals; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Disea | 2015 |
Low expression of Gria1 and Grin1 glutamate receptors in the nucleus accumbens of Spontaneously Hypertensive Rats (SHR).
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Gene Expression; Glycine Plasma Me | 2015 |
Maturation- and sex-sensitive depression of hippocampal excitatory transmission in a rat schizophrenia model.
Topics: Animals; Disease Models, Animal; Excitatory Postsynaptic Potentials; Female; Hippocampus; Male; Orga | 2016 |
A potential mechanism underlying atypical antipsychotics-induced lipid disturbances.
Topics: Animals; Antipsychotic Agents; Blotting, Western; Cholesterol; Clozapine; Corticosterone; Disease Mo | 2015 |
Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model.
Topics: Amino Acid Sequence; Animals; Binding Sites; Cognition; Disease Models, Animal; Doxycycline; Female; | 2015 |
Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.
Topics: Animals; Antipsychotic Agents; Cognition; Cognition Disorders; Conditioning, Operant; Disease Models | 2016 |
Comparison of phencyclidine-induced spatial learning and memory deficits and reversal by sertindole and risperidone between Lister Hooded and Wistar rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relations | 2016 |
ADN-1184, a monoaminergic ligand with 5-HT6/7 receptor antagonist action, exhibits activity in animal models of anxiety.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Aripiprazole; Behavior, Animal; Benzodiazepines; Conditioning | 2016 |
Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System Stimul | 2016 |
Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia.
Topics: Amphetamine; Animals; Behavior, Animal; Brain; Celecoxib; Disease Models, Animal; Drug Therapy, Comb | 2016 |
Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antidepressive Agents; Antipsychotic Agents; Benza | 2016 |
Detrimental effect of clomipramine on hippocampus-dependent learning in an animal model of obsessive-compulsive disorder induced by sensitization with d2/d3 agonist quinpirole.
Topics: Analysis of Variance; Animals; Avoidance Learning; Clomipramine; Disease Models, Animal; Dopamine Ag | 2017 |
Reversal of schizophrenia-like symptoms and immune alterations in mice by immunomodulatory drugs.
Topics: Animals; Antipsychotic Agents; Brain; Disease Models, Animal; Immunologic Factors; Immunomodulation; | 2017 |
In utero exposure to atypical antipsychotic drug, risperidone: Effects on fetal neurotoxicity in hippocampal region and cognitive impairment in rat offspring.
Topics: Analysis of Variance; Animals; Animals, Newborn; Antipsychotic Agents; Apoptosis; Avoidance Learning | 2017 |
Risperidone ameliorated Aβ
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Apoptosis; | 2017 |
Importance of intervention timing in the effectiveness of antipsychotics.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Disease Models, Animal; Dopamine; Male; Motor Activi | 2018 |
Repeated risperidone administration during puberty prevents the generation of the aggressive phenotype in a developmentally immature animal model of escalated aggression.
Topics: Age Factors; Aggression; Animals; Animals, Newborn; Antipsychotic Agents; Behavior, Animal; Body Wei | 2008 |
Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats.
Topics: Analysis of Variance; Animals; Body Temperature; Disease Models, Animal; Dopamine; Dopamine Antagoni | 2008 |
Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors.
Topics: Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal | 2008 |
N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia.
Topics: Acoustic Stimulation; Amphetamine; Animals; Antipsychotic Agents; Biological Clocks; Central Nervous | 2009 |
Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Benzodiazepines; Conditioning, | 2009 |
Asenapine effects in animal models of psychosis and cognitive function.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Attention; Benzodiazepines; Cognition; Dibe | 2009 |
The d-amphetamine-treated Göttingen miniature pig: an animal model for assessing behavioral effects of antipsychotics.
Topics: Animals; Antipsychotic Agents; Dextroamphetamine; Disease Models, Animal; Dose-Response Relationship | 2009 |
Tryptophan depletion impairs object-recognition memory in the rat: reversal by risperidone.
Topics: Animals; Brain; Chromatography; Diet; Disease Models, Animal; Hydroxyindoleacetic Acid; Male; Memory | 2010 |
The dose-dependent effect of chronic administration of haloperidol, risperidone, and quetiapine on sexual behavior in the male rat.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Dibenzothiazepines; Disease Models, Animal; Dop | 2011 |
Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia.
Topics: Age Factors; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Disease Models, Animal; Female; | 2011 |
Studies on the acute toxicity, pharmacokinetics and pharmacodynamics of paliperidone derivatives--comparison to paliperidone and risperidone in mice and rats.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dizocilpine Maleate; Electrocardiography; Exc | 2010 |
Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Clozapine | 2011 |
Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Catalepsy; Cholinergic Antagoni | 2011 |
Fluoxetine but not risperidone increases sociability in the BTBR mouse model of autism.
Topics: Animals; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Fluoxetine; Male; Mice; Risper | 2011 |
Chronic risperidone normalizes elevated pro-inflammatory cytokine and C-reactive protein production in omega-3 fatty acid deficient rats.
Topics: Animals; Antipsychotic Agents; C-Reactive Protein; Chronic Disease; Cytokines; Diet, Fat-Restricted; | 2011 |
Gastroprotective potential of risperidone, an atypical antipsychotic, against stress and pyloric ligation induced gastric lesions.
Topics: Animals; Antipsychotic Agents; Capillary Permeability; Dinoprostone; Disease Models, Animal; Dopamin | 2011 |
Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver.
Topics: Animals; Antipsychotic Agents; Cells, Cultured; Disease Models, Animal; Fatty Acid Synthases; Female | 2011 |
Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Antipsychotic Agents; Anxiety; Avoidance Learni | 2011 |
Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activation.
Topics: Amphetamine; Animals; Animals, Newborn; Antipsychotic Agents; Central Nervous System Stimulants; Dis | 2011 |
Modeling mania: Further validation for Black Swiss mice as model animals.
Topics: Amphetamine; Animals; Animals, Outbred Strains; Behavior, Animal; beta Catenin; Bipolar Disorder; Br | 2011 |
Metformin: an effective attenuator of risperidone-induced insulin resistance hyperglycemia and dyslipidemia in rats.
Topics: Animals; Antipsychotic Agents; Blood Glucose; Disease Models, Animal; Dyslipidemias; Glyburide; Huma | 2011 |
Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dizocilpine Maleate; Extracellular Space; Fem | 2011 |
Pallidal hyperdopaminergic innervation underlying D2 receptor-dependent behavioral deficits in the schizophrenia animal model established by EGF.
Topics: Aging; Animals; Animals, Newborn; Antipsychotic Agents; Behavior, Animal; Biomarkers; Catalepsy; Dis | 2011 |
Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation.
Topics: Animals; Anti-Inflammatory Agents; Cerebral Cortex; Disease Models, Animal; Down-Regulation; Encepha | 2013 |
Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Disease Models, Animal; Female; Haloperi | 2012 |
Risperidone reverses phencyclidine induced decrease in glutathione levels and alterations of antioxidant defense in rat brain.
Topics: Animals; Antioxidants; Antipsychotic Agents; Brain; Disease Models, Animal; Female; Glutamate-Cystei | 2012 |
GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction.
Topics: Animals; Autistic Disorder; Baclofen; Disease Models, Animal; Evoked Potentials, Auditory; Explorato | 2012 |
NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Dextroamphetamine; Disease Models, Animal; Dose | 2012 |
Risperidone attenuates the increase of extracellular nitric oxide and glutamate levels in serotonin syndrome animal models.
Topics: 5-Hydroxytryptophan; Animals; Brain; Clorgyline; Disease Models, Animal; Fluoxetine; Glutamic Acid; | 2012 |
Variable maternal stress in rats alters locomotor activity, social behavior, and recognition memory in the adult offspring.
Topics: Adrenergic Uptake Inhibitors; Amphetamine; Animals; Antipsychotic Agents; Atomoxetine Hydrochloride; | 2013 |
Chronic administration of risperidone in a rat model of schizophrenia: a behavioural, morphological and molecular study.
Topics: Age Factors; Animals; Animals, Newborn; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; | 2013 |
Low dose risperidone attenuates cue-induced but not heroin-induced reinstatement of heroin seeking in an animal model of relapse.
Topics: Analgesics, Opioid; Animals; Conditioning, Operant; Cues; Disease Models, Animal; Dopamine Antagonis | 2013 |
The atypical antipsychotic risperidone reverses the recognition memory deficits induced by post-weaning social isolation in rats.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Conditioning, Psychological; Discrimination Learnin | 2013 |
Antidyskinetic effects of risperidone on animal models of tardive dyskinesia in mice.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relations | 2003 |
Risperidone reduces limited access alcohol drinking in alcohol-preferring rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine D2 Rec | 2003 |
Peripheral injection of risperidone, an atypical antipsychotic, alters the body weight gains of rats.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Injections, Subcutaneous; Rats; Risperidone; | 2003 |
[Altered behavioral response to centrally acting drugs in mice lacking PACAP].
Topics: Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Disease Model | 2003 |
Haloperidol versus risperidone on rat "early onset" vacuous chewing.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dose-Respons | 2004 |
Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome.
Topics: 5-Hydroxytryptophan; Animals; Body Temperature; Clorgyline; Disease Models, Animal; Dizocilpine Male | 2004 |
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Administration, Oral; Animals; Antipsychotic Agents; Basal G | 2004 |
Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Behavior, Animal; Disease Mod | 2005 |
Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chlorpromazine; Clozapine; Cross-Over Studies | 2007 |
Behavioural effects of chronic haloperidol and risperidone treatment in rats.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Disease Models, Animal; Dopamine Antagonists; | 2006 |
Propranolol blocks chronic risperidone treatment-induced enhancement of spatial working memory performance of rats in a delayed matching-to-place water maze task.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; | 2007 |
Risperidone exerts potent anti-aggressive effects in a developmentally immature animal model of escalated aggression.
Topics: Age Factors; Aggression; Analysis of Variance; Animals; Antipsychotic Agents; Cricetinae; Disease Mo | 2007 |
Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dopam | 2007 |
Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro.
Topics: Animals; Antipsychotic Agents; Blotting, Western; Cell Line; Disease Models, Animal; Enzyme-Linked I | 2007 |
Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia.
Topics: Adult; Alleles; Animals; Antipsychotic Agents; Behavior, Animal; Chi-Square Distribution; Disease Mo | 2007 |
Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Cognition Disorder | 2007 |
Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats.
Topics: Animals; Antipsychotic Agents; Attention; Benzodiazepines; Clozapine; Cognition Disorders; Dibenzoth | 2007 |
The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Arginine Vasopressin; Clozapine; Deamino Argini | 2007 |
In vitro and in vivo demonstration of risperidone implants in mice.
Topics: Animals; Behavior, Animal; Biocompatible Materials; Disease Models, Animal; Drug Delivery Systems; D | 2008 |
Pemoline (2-amino-5-phenyl-1,3-oxazol-4-one)-induced self-injurious behavior: a rodent model of pharmacotherapeutic efficacy.
Topics: Animals; Antipsychotic Agents; Central Nervous System Stimulants; Disease Models, Animal; Fructose; | 2008 |
Distinct neurobehavioral consequences of prenatal exposure to sulpiride (SUL) and risperidone (RIS) in rats.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Brain; Conditioning, Psychological; Di | 2008 |
The chakragati mouse shows deficits in prepulse inhibition of acoustic startle and latent inhibition.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Clozapine; Conditioning, Psychological; Disease | 2008 |
Olanzapine and risperidone block a high dose of methamphetamine-induced schizophrenia-like behavioral abnormalities and accompanied apoptosis in the medial prefrontal cortex.
Topics: Animals; Antipsychotic Agents; Apoptosis; Behavior, Animal; Benzodiazepines; Disease Models, Animal; | 2008 |
[Behavioral assessment of neuroleptics (3)--Schizophrenia negative symptoms-like model induced by PCP].
Topics: Animals; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Clozapine; Desipramine; Disease Mod | 1996 |
Evaluation of risperidone in the neonatal 6-hydroxydopamine model of Lesch-Nyhan syndrome.
Topics: Animals; Animals, Newborn; Behavior, Animal; Benzazepines; Disease Models, Animal; Dopamine Agents; | 1998 |
Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; No | 1999 |
Risperidone counteracts lethality in an animal model of the serotonin syndrome.
Topics: 5-Hydroxytryptophan; Animals; Antidepressive Agents; Body Temperature; Clorgyline; Disease Models, A | 2000 |
Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Caudate Nucleus; Clozapine; Disease Models, Animal; Dose-Response Rel | 2002 |